Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M9466 (PARP1 inhibitor) in combination with topoisomerase 1 inhibitor-based regimens in advanced solid tumors and colorectal cancer
NCT06509906Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of M9466 in solid tumor (advanced stage) and colorectal cancer (CRC) (2 arms), sponsored by EMD Serono. Primary endpoints: Treatment-Emergent Adverse Events up to 18.7 months and Dose Limiting Toxicity. Started Oct 2024; status: terminated.
02
Drugs
M9466
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06509906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509906.